A Phase 1/2 interventional study of Campath and Palifermin in X-linked Severe Combined Immunodeficiency (XSCID), sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Recruiting at 1 site in United States. Open to male participants aged 2 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in X-Linked Combined Immunodeficiency Diseases with a site in United States — 5 open to participants now, 7 under way, none of them phase 3. X-Linked Combined Immunodeficiency Diseases · United States.
Among the 20 studies in X-Linked Combined Immunodeficiency Diseases with a site in United States, this one is the 2nd largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2012, is one of 8 in phase 1/2, and was the 12th registered.
28 studies on the registry are indexed under X-Linked Combined Immunodeficiency Diseases; 9 are open to participants now.
Browse X-Linked Combined Immunodeficiency Diseases studies →5 of the 20 studies in X-Linked Combined Immunodeficiency Diseases with a site in United States are open now. Recruiting first, the newest first:
David Williams · Sites in United States
Ages 0–5 · Men only
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Healthy volunteers
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 3–99 · Men only
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States, Canada
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 6 X-Linked Combined Immunodeficiency Diseases studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.
This study: 2 Years to 50 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 8
First in 1997; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is above the median of 9 across 16 interventional studies indexed under X-Linked Combined Immunodeficiency Diseases.
Median enrollment 12 across the 11 interventional studies, 478 across the 8 observational. Of the 8 that completed or were terminated, 3 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 20 have an industry lead sponsor. The 10 most frequent:
National Institute of Allergy and Infectious Diseases (NIAID) is the lead sponsor of 2,449 studies on the registry; 181 are open to participants now.
Of its 406 completed or terminated interventional studies of FDA-regulated products, 303 (75%) have results posted.
National Institute of Allergy and Infectious Diseases (NIAID) has 8 studies filed under X-Linked Combined Immunodeficiency Diseases — fewer than ten, so there is no comparison to draw.
1 of the studies in X-Linked Combined Immunodeficiency Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies in X-Linked Combined Immunodeficiency Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase I/II clinical trial will study the safety and potential benefits of gene therapy for up to 35 people aged 2 to 50 with X-linked severe combined immunodeficiency (XSCID), a rare genetic condition that makes it difficult to fight infections.
The study is for patients with XSCID who have serious immune system problems, including those who continue to experience serious immune complications after a previous stem cell transplant, and who do not have a suitably matched sibling donor. Treatment uses the patient s own blood-forming stem cells, which are collected from the bloodstream. In a laboratory, a specially designed delivery system called a lentiviral vector adds a working copy of the affected gene to these cells to help them produce functioning immune cells.
Before receiving the modified cells, patients will receive a reduced dose of busulfan, a chemotherapy medicine that makes room in the bone marrow for the treated cells. The dose may be further adjusted according to the study protocol, including for patients with significant organ damage. Alemtuzumab (Campath) may also be given when clinically indicated, including to address certain immune problems involving donor T cells from a previous transplant. The modified stem cells will then be returned through a single infusion into a vein.
Researchers will monitor side effects, how well the modified cells survive and produce immune cells, and whether patients develop stronger immune function and better health. The main assessment will occur two years after treatment, with follow-up visits continuing through year five. A separate long-term follow-up study will monitor patients through year 15 for lasting benefits and delayed side effects, including cancer. This treatment is experimental, and its benefits and risks are not yet fully known....
This is a non-randomized clinical trial of gene transfer using a self-inactivating, insulated, lentiviral gene transfer vector to treat 35 patients with X-linked severe combined immunodeficiency (XSCID, also called SCID-X1) who are between 2 and 50 years of age; who do not have a tissue matched sibling who can donate bone marrow for a transplant; who may have failed to obtain sufficient benefit from a previous half-tissue matched bone marrow transplant; and who have clinically significant impairment of immunity. A patient's own precursor cells (also called blood stem cells) that give rise in the marrow to blood and immune cells will have been or will be collected from the patient's blood or bone marrow. A patient will not proceed to gene transfer treatment in this protocol until there are at least 3 million blood stem cells per kilogram body weight collected from the patient. At the NIH the patient blood stem cells will be cells collected previously under NIH protocol 94-1-0073 or collected on this protocol. In most cases the harvested blood stem cells are put into frozen storage before use in this protocol. When the patient enrolled in this protocol has the required number of blood stem cells harvested, then the patient's blood stem cells will be grown in tissue culture and exposed to the lentiviral gene transfer vector containing the corrective gene. These gene-corrected blood stem cells will be administered through the patient's vein. To increase engraftment of the corrected blood stem cells, patients will receive a chemotherapy drug called busulfan at a total dose of 6 mg/kilogram body weight (3 mg/kilogram body weight/daily) for two days before the gene transfer treatment. The busulfan dose used in this study is a little more than one-third the dose used in many standard bone marrow transplants. To improve patient safety, those with significant organ damage may receive reduced busulfan dose of a total 4mg/kg with 2mg/kg dose given on Day 1, and dose adjusted on day 2 to achieve AUC of 6000 min*umol/L. Subjects who mobilize poorly (total CD34+ cells \<5 million/kg) may use all their cells for product manufacture without leaving backup aliquot of 1e6/kg.
For patients who have clinical problems related to donor T cell dysregulation, alemtuzumab (Campath) may be administered. Patients will also be given another drug called palifermin that helps prevent the main side effect from the busulfan, which is a type of inflammation of the mouth, stomach and bowels called mucositis. After the gene transfer treatment, patients will be monitored to see if the treatment is safe and whether their immune system improves. Patients will be followed at frequent intervals for the first 2 years, and less frequently thereafter so that the effectiveness in restoration of immune function and the safety of the treatment can be evaluated.
XSCID is a genetic disease caused by defects in common gamma chain, a protein found at the surface of immune cells called lymphocytes and is necessary for their growth and function. XSCID patients cannot make T-lymphocytes necessary to fight infections, and their B-cells fail to make essential antibodies. Without normal T- and B-lymphocyte function, patients develop fatal infections in infancy unless they receive a bone marrow transplant from a healthy donor. The best type of transplant is from a tissue-matched healthy brother or sister, but most XSCID patients do not have a tissue-matched sibling and are treated with a transplant from a parent who is only half- matched by tissue typing. While a half-matched transplant from a parent can be lifesaving for an infant with XSCID, a subset of patients fails to achieve sufficient long lasting restoration of immunity to prevent infections and other chronic problems. Trials of gene transfer treatments using mouse retrovirus vectors for infants with XSCID have been performed and have demonstrated that this type of gene transfer can be an alternate approach for significantly restoring immunity to infants with XSCID. However, among the 18 infants with XSCID benefiting long-term from the gene transfer treatment, 5 developed Tlymphocyte leukemia and 1 died of this leukemia. Furthermore, when older children with XSCID were treated with gene transfer, the restoration of immunity was much less than seen in the infants. These observations of gene transfer treatments using mouse retrovirus vectors to treat infants and older patients with XSCID suggest that safer and more effective vectors were needed, and that there also may be a need to give chemotherapy or other method of conditioning to increase engraftment in the marrow of the gene corrected blood stem cells. Our data and other published studies suggest that lentivectors that are derived from the human immunodeficiency virus and have the properties of our highly modified vector called CL20-4i-EF1alpha- h-gamma-c-OPT have a reduced interaction with nearby genes and therefore less of a tendency to activate genes that may lead to cancer formation. Also, this type of lentivector may work better at getting into blood stem cells.
The purpose of this study is to evaluate the safety and effectiveness of the lentiviral gene transfer treatment at restoring immune function to XSCID patients who are 2 to 50 years of age and have significant impairment of immunity. Early evidence for effectiveness will be defined by appearance and expansion in the circulation of the patient's own gene corrected T-lymphocytes with a functional gamma-c gene and improved laboratory measures of immune function. The primary endpoint for efficacy will be assessed 2 years after treatment and will include these laboratory parameters plus evidence for clinical benefit. Evidence for safety will focus on the maintenance of a diversity of gene marked cells and no occurrence of abnormal patterns of production of blood cells or any leukemia or other cancer. The primary study endpoints for all laboratory and clinical measures of efficacy and safety will occur at 2 years after gene transfer treatment. However, data collection regarding efficacy will occur at frequent intervals during the 2 years leading up to the endpoint analysis, through study completion at 5 years. Safety and efficacy evaluations will continue yearly under a separate NIH study during the long-term follow-up period recommended by the United States FDA for patients participating in gene transfer treatment studies.
The criteria were revised on the registry on Oct 19, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants of must agree to consistently use highly effective throughout study participation and for at least 2 years post-treatment. Acceptable forms of contraception are:
--For males: Condoms or other contraception with partner.
Laboratory Criteria: (>=1 must be present)
I. CD4+ lymphocytes: absolute number \<= 50% of the lower limit of normal (LLN)
II. CD4+ 5RA+ lymphocytes: absolute number \<= 50% of the LLN OR T-cell receptor excision circles (TRECs) \<= 5% of normal for age.
III. Memory B Cells: absolute number \<= 50% of LLN
IV. Serum IgM\<normal for age
V. NK cells: absolute number \<= 50% of LLN
VI. Lymphocyte proliferative response to each of 2 mitogens, phytohemagglutinin (PHA) and concanavalin A (ConA), is \<= 25% compared with a normal control.
VII. Molecular spectratype analysis- absent or very oligoclonal (1-3 dominant peaks) in >=6 of the 24 VBeta T-cell receptor families.
Clinical Criteria: (>=1 must be present):
I. Infections (not including molluscum, warts or mucocutaneous candidiasis; see vii and viii below):
Three significant new or chronic active infections during the 2 years preceding evaluation for enrollment, with each infection accounting for one criteria.
Infections are defined as an objective sign of infection (fever >38.3 degrees C [101 degrees F] or neutrophilia or pain/redness/swelling or radiologic/ultrasound imaging evidence or typical lesion or histology or new severe diarrhea or cough with sputum production). In addition to one or more of these signs/symptoms of possible infection, there also must be at least 1 of the following criteria as evidence of the attending physician's "intent to treat" a significant infection (a. and b.) or objective evidence for a specific pathogen causing the infection (c.)
Treatment (not prophylaxis) with systemic antibacterial, antifungal or antiviral antibiotics 14 days
OR
Hospitalization of any duration for infection
OR
II. Chronic pulmonary disease as defined by:
Bronchiectasis by x-ray computerized tomography
OR
Pulmonary function test (PFT) evidence for restrictive or obstructive disease that is 60% of Predicted for Age
OR
III. Gastrointestinal enteropathy:
Diarrhea-watery stools 3 times per day (of at least 3 months duration that is not a result of infection as defined in criterion # i. above)
OR
Endoscopic evidence (gross and histologic) for enteropathy (endoscopy will only be performed if medically indicated)
OR
IV. Poor nutrition: Requires G-tube or intravenous feeding supplement to maintain weight or nutrition.
V. Auto- or allo-immunity: Examples must include objective physical findings that include, but are not limited to any one of alopecia, severe rashes, uveitis, joint pain with redness or swelling or limitation of movement that is not a result of infection, lupus-like lesions, and granulomas (Does not include auto- or allo-immune enteropathy which is criterion iii). Where possible and appropriate, diagnosis will be supported by histopathology or other diagnostic modality.
VI. Failure to grow in height: \<=3rd percentile for age
VII. Skin molluscum contagiosum OR warts (this criterion is satisfied if molluscum consists of 10 lesions or there are two or more lesions at each of two or more widely separated anatomic sites; or there are 3 warts at different anatomic sites at the same time; or the patient has both molluscum and warts)
VIII. Mucocutaneous candidiasis (chronic oral thrush or candida esophagitis or candida intertriginous infection or candida nail infections; must be culture positive to satisfy this criterion)
IX. Hypogammaglobulinemia: requires regular IgG supplementation
Criteria for eligibility for Campath (alemtuzumab):
Evidence of organ disease attributable to T cell dysregulation, for example, elevated transaminases.
EXCLUSION CRITERIA:
NOTE: Alemtuzumab (Campath) is no longer distributed commercially. To receive product, the physician must contact the program for the participant. If Campath use is indicated and the participant is not willing to consent to submit their info (demographics, contact information, and rationale for use) to the program such that we can obtain the drug, then the participant will not undergo gene therapy and will be withdrawn.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
First 8 Patients Treated
Drug: Palifermin · Drug: Busulfan · Biological: Ex vivo culture and transduction of the patient's autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4i-EF1alpha-hgammac-OPT vector
Patients 9 and Beyond
Drug: Campath · Drug: Palifermin · Drug: Busulfan · Biological: Ex vivo culture and transduction of the patient's autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4i-EF1alpha-hgammac-OPT vector
May be administered subcutaneously Days -21 through Day -19 in patients who demonstrate evidence of donor T cell dysregulation
Mucositis prophylaxis commenced- Infusion of keratinocyte growth factor (palifermin) at 60 mcg/kg/day before (Days -6 to Day -4) administration of busulfan and (Days +1 to +3) post-busulfan administration
3mg/kg per day with drug levels obtained on Day -3. Busulfan dose on day -2 will be adjusted (if busulfan AUC result is available) to achieve targeted busulfan AUC 4500 min\*umol/L/day. Dose reduction to a total dose of 4mg/kg (target AUC 6000 min\*umol/L/day) may be offered to patients with significant organ damage
Transduced cell product administered intravenously over approximately 30 minutes by authorized licensed personnel consistent with NIH Clinical Center Department of Transfusion Medicine's standard operating procedures for cellular products.
Early evidence for efficacy will be defined by appearance and expansion in the circulation of autologous transduced T-lymphocytes with functional gmama-c and improved laboratory measures of immune function in the interim evaluation of these para...
successful, partial successful or failure
Time frame: 1 year
evidence for efficacy at 2 years after treatment will include these same laboratory parameters measured at the 2 year time point plus evidence for clinical benefit
maintenance of polyclonality of vector marking, the lack of emergence of a dominant gene marked clone in any hematopoietic lineage, and no occurrence of either hematologic dysplasia or any leukemia or other cancer resulting from the gene transfer
Time frame: 2 years
Plan to share: Undecided — The PI has yet to determine how IPD will be shared.
Started Sep 2012 (actual). Primary completion is estimated for Dec 2032, 243 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alemtuzumab
X-Linked Combined Immunodeficiency Diseases →
National Institute of Allergy and Infectious Diseases (NIAID) →